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Abstract
Introduction: Studies in the spontaneous ankylosis model in aging male DBA/1 mice and in patients with
ankylosing spondylitis provide evidence that inflammation and new tissue formation leading to joint or spine
ankylosis are likely linked but largely uncoupled processes. We previously proposed the ‘entheseal stress’ hypothesis
that defines microdamage or cell stress in the enthesis as a trigger for these disease processes. Here, we further
investigated the relationship between inflammation and ankylosis by focusing on the early phase of the
spontaneous arthritis model.
Methods: Aging male DBA/1 mice from different litters were caged together at the age of ten weeks and studied
for signs of arthritis. A group of DBA/1 mice were treated daily with dexamethasone (0.5 μg/g body weight).
Severity of disease was assessed by histomorphology and by positron emission tomography (PET) using 2-[18F]
fluoro-2-deoxy-D-glucose (18F-FDG) as a tracer. Bone loss in dexamethasone-treated or control mice was
determined by in vivo dual-energy X-ray absorptiometry. Chemokine gene expression was studied ex vivo in
dissected paws and in vitro in mesenchymal cells (periosteal and bone marrow stromal cells) by quantitative real-
time PCR in the presence or absence of bone morphogenetic protein 2 (BMP2) and dexamethasone.
Results: Dexamethasone treatment did not affect incidence or severity of ankylosis, but led to an expected
reduction in inflammation in the paws at week 15 as measured by PET tracer uptake. Treatment with
dexamethasone negatively affected bone mineral density. Chemokines attracting neutrophils and lymphocytes
were expressed in affected paws. In vitro, BMP2 stimulation upregulated chemokines in different mesenchymal
joint-associated cell types, an effect that was inhibited by dexamethasone.
Conclusions: BMP signaling may be a trigger for both inflammation and ankylosis in the spontaneous model of
ankylosing enthesitis. The lack of inhibition by glucocorticoids on new bone formation while causing systemic
bone loss highlights the paradoxical simultaneous loss and gain of bone in patients with ankylosing spondylitis.
Introduction
Ankylosing spondylitis (AS) and related spondyloarthri-
tides (SpA) are common chronic inflammatory joint dis-
eases with severe impact on patients and society [1,2].
Inflammation is held responsible for many of the signs
and symptoms of disease but the long-term prognosis for
patients with AS is also determined by progressive ankylo-
sis of the spine due to new cartilage and bone formation
[3]. Remarkably, new bone formation at the bone borders
occurs simultaneously with inflammation-induced loss of
trabecular bone leading to osteoporosis [4,5].
Although traditionally viewed as a repair response, we
hypothesized that ankylosis is a specific and primary
aspect of AS and proposed the entheseal stress hypoth-
esis which explains how inflammation and ankylosis are
linked but largely uncoupled processes [6]. In this con-
cept, microdamage or cell stress in the enthesis triggers
both an inflammatory and a bone anabolic response lead-
ing to the clinical development of AS and the typical
radiographic signs of disease. Specific environmental and
genetic factors are suggested to influence chronicity of
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the inflammatory response and progression of ankylosis
[6].
The introduction of anti-tumor necrosis factor (TNF)
strategies has been a breakthrough for patients with AS
and other SpAs [2]. These drugs have an unprecedented
effect on symptoms of disease. However, recent data in
mice and men suggest that control of inflammation with
TNF blocking agents is not sufficient to prevent progres-
sive ankylosis [7-10]. Therefore, in contrast to what is seen
in patients with rheumatoid arthritis, anti-TNF appears to
fail to inhibit radiographic progression of disease in AS
[11,12].
DBA/1 mice spontaneously develop arthritis of the hind
paws characterized by entheseal ankylosis upon grouped
caging of males from different litters [13]. In this mouse
model both anti-TNF treatment using human soluble
receptor etanercept and anti-osteoclast strategies using
zoledronic acid are not sufficient to inhibit new bone for-
mation [7,14]. In contrast, overexpression of noggin, a
bone morphogenetic protein (BMP) antagonist, reduced
the incidence and severity of the murine arthritis [15].
The specific role of inflammation in this model remains
unclear. We have demonstrated a short-lived inflamma-
tory phase characterized by edema and neutrophil infiltra-
tion in the affected toes, likely preceding the remodeling
phase [13]. Here we focused on these early inflammatory
events, the interactions between BMPs and inflammation
and the complex effects of glucocorticoids, drugs with
strong anti-inflammatory and anti-bone anabolic effects,
in the spontaneous model.
Materials and methods
Animal experiments
Male DBA/1 mice were obtained from Janvier (Le Genest
St Isle, France). All experiments were approved by the
Ethics Committee for Animal Research (KU Leuven, Bel-
gium). Male mice from different litters were mixed and
caged in groups of six mice at the age of ten weeks. Mice
were treated daily with dexamethasone (0.5 mg/kg; Rotex-
medica, Trittau, Germany) or phosphate buffered saline
(PBS) by intraperitoneal injection from the age of
12 weeks onwards (n = 10 and 12 mice per group, respec-
tively). Mice were scored blindly twice a week for clinical
signs of arthritis [13,16]: 0 (no symptoms), 1 (redness and
swelling in one toe), 2 (redness and swelling in more than
one toe), 3 (toe stiffness), and 4 (deformity or ankle invol-
vement). Hind paw forefeet were studied by histomorphol-
ogy as described [13,16]: 0 (normal toe), 1 (acute
inflammation including dactylitis), 2 (entheseal cell prolif-
eration), 3 (cartilage formation), 4 (bone formation), and
5 (joint ankylosis). A cumulative score from all toes was
calculated. In additional experiments, paws of control
mice of 12 and 16-week-old DBA/1 mice were used for
gene expression analysis.
Imaging studies: small animal Positron Emission
Tomography (PET) imaging and Dual Energy X-ray
Absorptiometry (DEXA)
The mice were imaged using a Focus 220 microPET®
scanner (Concorde Microsystems Inc., Knoxville, TN,
USA). The mice were anesthetized with 2.5% isoflurane in
100% oxygen at a flow rate of 1 L/minute and 7.4 MBq of
2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) was adminis-
tered by lateral tail vein injection. One hour after injection
a ten minute static scan was acquired. Images were recon-
structed using a maximum a posteriori algorithm from the
vendor with 18 iterations and uniform resolution. The
images were displayed in Amide’s a Medical Imaging Data
Examiner (AMIDE) [17] and three-dimensional spheroid
regions of interest (ROIs) were drawn over the toes, the
paws and within a reference region (liver). The mean
radioactivity in the ROIs was converted to percent of the
injected dose per gram of tissue (%ID/g) by a calibrated
cylinder factor and after division with the injected dose
(corrected for residual and decay). Standardized uptake
values (SUV) were obtained by multiplying the % ID/g of
the toe area by the weight of the animal.
Bone mineral content was assessed by dual X-ray
absorptiometry using Piximus densitometer (Lunar,
Madison, WI, USA) [18].
Cell culture
Human periosteum-derived cells (hPDCs) were isolated as
described [19]. Human bone marrow cells (hBMCs) were
isolated by standard aspiration from freshly isolated bone
marrow as described previously [20]. hPDCs and hBMCs
were expanded in complete culture medium consisting of
high-glucose Dulbecco’s Modified Eagle Medium
(DMEM)/Glutamax (4.5 g/l of glucose) (Invitrogen, Merel-
beke, Belgium) supplemented with 10% fetal bovine serum
(Gibco, Merelbeke, Belgium), antibiotic-antimycotic solu-
tion (100 units/ml penicillin, 100 μg/ml streptomycin and
0.25 μg/ml amphotericin B; Invitrogen) and sodium pyru-
vate (Gibco). hPDCs and hBMCs were seeded at a density
of 12 × 104 c/ml in 24-well plates. After overnight adher-
ence, cells were stimulated with 3 to 30 ng/ml BMP2
(R&D Systems, Minneapolis, MN, USA) with or without 1
μM dexamethasone (Rotexmedica). After a 24-hour incu-
bation, samples were collected for RNA analysis.
RNA isolation and Real-Time RT-polymerase chain
reaction (PCR)
For gene expression analysis of mouse tissues, hind paws
of 12 and 16 week old mice were dissected just above
the ankle joint and skin was removed. Total RNA was
isolated using the standard Nucleospin RNAII kit
(Macherey-Nagel, Düren, Germany) protocol. Comple-
mentary DNA was obtained by reverse transcription of
0.5 to 1 μg of total RNA using the RevertAid H Minus
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First Strand cDNA synthesis kit (Fermentas, Rockford,
IL USA) following the manufacturer’s instructions. For
quantitative analysis, real-time RT-PCR was performed
using Perfecta qPCR FastMix (Quanta Biosciences, Inc.,
Gaithersburg, MD, USA) carried out on a Corbett
Rotor-Gene 6000 system (Corbett Research, Westburg,
Leusden, The Netherlands). The expression of the fol-
lowing genes was examined: human chemokine (C-X-C
motif) ligand 1 (CXCL1), granulocyte chemotactic pro-
tein 2 (GCP2), and inhibitor of DNA binding 1 (ID1)
and mouse homolog Cxcl1 and Gcp2 and mouse chemo-
kine (C-X-C motif) receptor 1 (Cxcr1) and Cxcr2.
Human and mouse glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH and Gapdh, respectively) were used
as housekeeping genes. Primer/probe sets for these
genes were commercially available Assay-on-demands
(Applied Biosystems, Lennik, Belgium).
Statistical analysis
For comparison between groups, Student’s t-test was
used. Results were considered statistically significant
with two-sided P-values < 0.05.
Results
Severity of arthritis in mice treated with dexamethasone
Daily injection of dexamethasone (0.5 mg/kg) from week
12 onwards did not inhibit clinical incidence or severity
of spontaneous arthritis in male DBA/1 mice as com-
pared to placebo-treated mice (Figure 1A-B). As the clin-
ical evaluation of this model can not distinguish
inflammatory and remodeling features, histomorphologi-
cal analysis was performed. We found no difference in
overall severity between dexamethasone-treated and con-
trol mice (Figure 1C). In addition, there was no signifi-
cant difference in pathological endochondral bone
formation between both groups (Figure 1D).
As expected dexamethasone treatment did signifi-
cantly affect mouse weight (Figure 2A) and total body
bone mineral content (Figure 2B), demonstrating that
local new bone formation leading to joint ankylosis can
occur simultaneously with systemic bone loss.
Control of inflammation by glucocorticoid treatment
Inflammation in the spontaneous arthritis model in
DBA/1 mice has been described previously as short-lived
and presenting as enthesitis or dactylitis. The process is
characterized by infiltration of mostly neutrophils and to
a lesser extent mononuclear inflammatory cells [13]. To
quantify inflammation in the paws in a dynamic way, ten
mice (four dexamethasone- and six placebo-treated) were
injected with 18F-FDG and uptake was measured by PET-
scan (Figure 3A). 18F-FDG has been shown to accumulate
in activated inflammatory cells (neutrophils and macro-
phages) and serves as a marker of inflammation [21].
Mice treated with dexamethasone showed significantly
lower tracer uptake at 15 weeks as compared to controls.
By week 20 uptake of the tracer was similar in both
groups (Figure 3B) and lower than at 15 weeks.
Presence of chemokines in SpAD
As neutrophils are the most common cells in the inflam-
matory reaction in this mouse model, we measured
expression of two chemokines (Cxcl1 and Gcp2) and
their receptors (Cxcr1 and Cxcr2), well-known mediators
of neutrophil migration to inflammatory sites, in male
DBA/1 mice at different time points (Figure 4A-D). Both
chemokines and their receptors are expressed in paws of
DBA/1 mice, with a proportion of the paws showing high
gene expression levels. The fold difference in gene
expression level of Cxcr1, Cxcr2, Cxcl1 and Gcp2
between the four paws with the highest level compared
to the four lowest levels was 5.0, 27.7, 7.2 and 2.5, respec-
tively at 12 weeks and 7.4, 6.3, 3.4 and 3.9 at 16 weeks. Of
note, clear clinical signs of disease in these mice were not
apparent corroborating our previous observations that
mild inflammatory changes in this model are not easily
detected by clinical observation only.
BMPs and chemokine upregulation
The entheseal stress hypothesis suggests that activation
of entheseal cells may be the initiating event in attracting
inflammatory cells [6]. Since earlier observation showed
that inhibition of BMP signaling in this model prevented
disease occurrence [15], we tested whether BMP2 could
induce neutrophil chemokines. Human progenitor cells
derived from either periost or bone marrow were stimu-
lated with different concentrations of BMP2 and treated
with 1 μM dexamethasone. Stimulation of hPDCs and
hBMCs resulted in a dose dependent increase of ID1, a
BMP target gene, and was not influenced by dexametha-
sone treatment (Figure 5A). Twenty-four hours of BMP2
stimulation induced the expression of GCP2 in hPDCs
and this induction was inhibited by dexamethasone (Fig-
ure 5B). A similar effect was suggested in hBMCs,
although the difference was not statistically significant.
CXCL1 was also significantly upregulated in hPDCs but
not in hBMCs (data not shown). Dexamethasone treat-
ment itself induced an increase in CXCL1 in vitro in both
hPDCs and hBMCs, but did not further stimulate or inhi-
bit the effect of BMP2.
Discussion
Patients who are suffering from AS show a remarkable
paradox in the skeleton. Inflammation appears associated
with osteoporosis of the trabecular bone, but also with
new bone formation occurring at the edges of the bone,
two contrasting features in close proximity. Targeted
therapies antagonizing TNF result in substantial clinical
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improvement, reduction of inflammation and inhibition
of bone loss in AS patients. In contrast, new bone forma-
tion leading to ankylosis does not appear to be inhibited
by anti-TNF therapy [7-10]. The entheseal stress hypoth-
esis challenges the paradigm that inflammation triggers
ankylosis and proposes a concept in which both inflam-
mation and new tissue formation in AS are secondary to
a common trigger, for example, cell stress or microdam-
age in the enthesis [6]. In the study presented here, glu-
cocorticoid treatment in mice developing spontaneous
arthritis characterized by ankylosing enthesitis appears to
affect inflammation without direct impact on joint remo-
deling. These observations parallel our earlier studies in
which we demonstrated that neither anti-TNF therapy
with etanercept nor osteoclast inhibition has a beneficial
effect on progression of ankylosis [7,14].
Glucocorticoid use does have a negative effect on bone
loss as demonstrated by DEXA analysis. Much like what is
seen in AS patients, loss and gain of bone appear simulta-
neously and in close proximity. This observation provides
support for the view that the molecular mechanisms of
ankylosis are disconnected from inflammation or bone
loss. These observations suggest that new bone formation
as seen in this model and also in patients with ankylosing
spondylitis is not dependent on the classical bone remo-
deling cycle essential for skeletal renewal and which is
affected in osteoporosis. Therefore, molecular mechanisms
leading to new bone formation and ankylosis are likely dif-
ferent from those guiding the physiological bone remodel-
ing cycle. Such a difference suggests that specific targeting
of ankylosis is feasible without necessarily interfering with
homeostatic bone remodeling.
We previously demonstrated that inhibition of BMP
signaling reduced the incidence and severity of sponta-
neous arthritis and ankylosis suggesting that BMP signals
are an upstream event in this mouse model [15]. Inflam-
mation in the spontaneous model is short-lived and the
clinical evaluation of the mice does not distinguish
between local joint swelling and redness caused by either
inflammation, cell proliferation or differentiation [13]. In
our experience, the inflammation phase of the model is
often discrete and not readily recognized during routine
Figure 1 Corticosteroid treatment does not affect clinical signs of spontaneous arthritis. (A) Cumulative incidence of arthritis and (B)
clinical severity score in dexamethasone-treated and control animals (n = 10 and 12 animals per group, respectively). (C) Dexamethasone
treatment does not affect histological severity of arthritis (ns: P = 0.2). Data in (B) and (C) are shown as mean ± SEM. (D) Effect of
dexamethasone treatment on different features of ankylosing enthesitis. Data in (D) are shown as percentage of affected paws exhibiting a
specific treat compared to the total number of affected paws. ns, nonsignificant; SEM, standard error of the mean.
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clinical examination of the mice. We, therefore, used 18F-
FDG PET scans to quantify inflammation in the model.
The lack of chronic inflammation is an intrinsic limita-
tion of this model, but the current observation that inhi-
bition of inflammation has no effect on ankylosis
corroborates our hypothesis that inflammation and new
tissue formation are largely independent events with a
potential common trigger.
Further experiments identified upregulation of neutro-
phil chemokines in the early phase of the model. Since
BMP inhibition was, in contrast to different anti-inflam-
matory strategies, capable of preventing clinical and his-
tomorphological signs of arthritis [15], we further
studied whether stromal cells could respond to BMPs by
upregulating specific chemokines. BMP-induced GCP2
expression occurred late after stimulation. No significant
GCP2 induction could be detected after an early time-
point (2-hour stimulation) as measured by gene expres-
sion analysis and ELISA by determination of GCP2 pro-
tein in the cell culture supernatant (data not shown).
Also, dexamethasone treatment did not affect BMP2
induced ID1 expression. Together, these results suggest
that the BMP-induced GCP2 expression is an indirect
effect.
Our data suggest that at least in this model activation
of the BMP signaling cascade can contribute to both
joint inflammation and remodeling (Figure 6). These
observations further corroborate the entheseal stress
hypothesis and provide support for a non-inflammatory
Figure 2 Dexamethasone treatment affects body weight and
whole body mineral content. (A) Body weights were measured
after two weeks of dexamethasone treatment. (B) Bone mineral
content was measured by DEXA at the end of the experiment (20
weeks). Data are shown as mean + SEM. (n = 12 control animals
and 10 dexamethasone-treated animals; * P < 0.05). DEXA, dual
energy X-ray absorptiometry; SEM, standard error of the mean.
Figure 3 Dexamethasone treatment influences the
inflammatory component of spontaneous arthritis as measured
by 18F-FDG PET scan. (A) Representative images of animals from
both treatment groups. The ‘toe’ area used for measurements is
indicated. (B) Standardized uptake values of the tracer
demonstrating a reduction in the uptake after dexamethasone
treatment at week 15. At week 20, the inflammatory component
has largely disappeared as seen in the control group. (n = 4 animals
in dexamethasone treated group and 6 control animals; * P < 0.05
dexamethasone treatment versus control group; # P < 0.05 week 20
versus week 15 in control group). 18F-FDG, 2-[18F]fluoro-2-deoxy-D-
glucose; PET, positron emission tomography.
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or non-specific primary cause of the arthritis with sub-
sequent involvement of both inflammation and remodel-
ing. In the specific entheseal micro-environment
complex feedback loops may exist in which TNF and
other cytokines stimulate the production BMP2. The
BMP2 promoter contains TNF responsive elements and
upregulation of BMP2 after TNF stimulation has been
demonstrated in different skeletal cell types [22,23].
Taking into account the broad immune-modulating
properties of glucocorticoids, we can not assume that
the presented interaction with BMP-induced chemokine
induction is the only or the main mechanism by which
dexamethasone treatment affects the inflammatory dis-
ease of the mouse model. Nevertheless, the observed
gene regulation provides an exciting link between signal-
ing pathways involved in joint remodeling and signals
contributing to inflammation. Such interactions are of
great interest when a comprehensive or system-biology
view of arthritis is developed.
A number of limitations of the current study need to be
considered. First, we preferred to use human progenitor
cells instead of mouse cells. Dissection and isolation pro-
cedures in the mouse can affect cell purity and it is also
difficult to expand mouse periost derived cells into large
amounts. hPDCs are periosteum derived progenitor cells
involved in bone development and postnatal repair pro-
cesses [19,24]. The periosteum, a fibrous tissue which
covers the bone surface, is known to participate in the
differentiation of chondrocytes and osteoblasts in frac-
ture healing [25]. Progenitor cells derived from the bone
marrow can be differentiated into osteoblasts and partici-
pate as well in bone fracture repair processes [26].
Figure 4 Quantitative PCR analysis of neutrophil chemokines and receptors in paws of male DBA/1 mice aged 12 and 16 weeks. The
expression levels of Cxcr1 (A), Cxcr2 (B), Cxcl1 (C) and Gcp2 (D) are shown. Y-axis displays gene expression values normalized to GAPDH and is
presented as log-scale (* 10-4). The average gene expression for each gene in both groups is presented by the horizontal line. PCR, polymerase
chain reaction.
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We preferred a broad non-specific anti-inflammatory
approach with glucocorticoids to target inflammation
in vivo rather than the inhibition of a specific chemo-
kine as the inflammatory events are likely driven by dif-
ferent chemokines. A number of small molecules
designed to inhibit chemokines are in clinical develop-
ment but the short-lived pharmacokinetics of such
molecules [27,28] are not suitable for the mouse model
used here as we demonstrated earlier for p38 inhibition
[29] and as suggested by human data using celecoxib in
ankylosing spondylitis [30]. Glucocorticoid treatment
allowed us to evaluate its effect on local bone formation
and systemic bone loss simultaneously.
Conclusions
This study highlights the paradoxical simultaneous loss
and gain of bone in a mouse model of AS and suggests
that BMPs may trigger both inflammation and ankylosis.
Further identification of factors that lead to the production
of BMPs in the enthesis appears, therefore, critical to
understand better the initiating events of the disease pro-
gress. Insights into these mechanisms based on functional
Figure 5 Gene expression analyses of ID1 and chemokines in human periosteal and bone marrow stromal cells. Cells were cultured for
24 hours in the presence or absence of BMP2 (3 or 30 ng/ml) and 1 μM dexamethasone. Y-axis displays gene expression levels of (A) ID1 and
(B) GCP2 normalized to housekeeping gene GAPDH. Values are expressed as fold increase relative to control condition (no BMP2, no
dexamethasone) and are presented as log scale (n = 3; * P < 0.05). BMP2, bone morphogenetic protein 2.
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and genomics studies may lead not only to the develop-
ment of new therapeutic approaches to control and
improve AS and related disorders but also to avoid radio-
graphic progression.
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